Les interactions CBD / médicaments Posté le 6 avril 2020 par Swiss Medical Cannabis Depuis l’augmentation de sa demande, le cannabidiol (CBD) attire significativement l’attention sur son potentiel à soulager les symptômes de l’insomnie, de l’anxiété, de la douleur chronique et d’une foule d’autres problèmes de santé. Les recherches menées à ce jour démontrent progressivement que le CBD est d’une grande sécurité d’emploi même à forte dose et peu d’effets secondaires, somme toute mineurs. Toutefois, il existe une mise en garde : le CBD peut interagir avec certains médicaments. L’interrogation porte ainsi sur la façon dont le corps métabolise certaines substances. Avant de [...]
Lire la suiteAdd-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial Elizabeth A. Thiele, MD, PhD; E. Martina Bebin, MD, MPA; Hari Bhathal, MD; Floor E. Jansen, MD; Katarzyna Kotulska, MD, PhD; John A. Lawson, BMed, PhD; Finbar J. O'Callaghan, MBChB, PhD; MichaelWong,MD, PhD; Farhad Sahebkar, MD; Daniel Checketts, MSc; Volker Knappertz, MD; for the GWPCARE6 Study Group JAMA Neurology, 2020, December 21 online, E1-E7. doi : 10.1001/jamaneurol.2020.4607 IMPORTANCE : Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as [...]
Lire la suiteCannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients Diana M. Martinez, MD Medscape .com, December 18, 2020 This transcript has been edited for clarity. Hello. I'm Diana Martinez. I'm a psychiatrist at the Columbia University Medical Center in the Department of Psychiatry. Today we'll be talking about the interaction between cannabis and psychiatric disorders. When I say "cannabis," this is really the same as marijuana. I use the term "cannabis" because this is a scientific term for the plant. I'm going to start with a brief history of cannabis. It’s been used for centuries in India as both an intoxicant and a [...]
Lire la suiteAdolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington Jeremy Mennis, Gerald J Stahler Drug and Alcohol Dependence, 2020 May 1, 210, 107960. doi : 10.1016/j.drugalcdep.2020.107960 Abstract Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008-2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12-17 were used to model state treatment admissions trends. [...]
Lire la suiteA Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers Daniel Perkins · Juliet Butler · Katherine Ong · Tri‑Hung Nguyen · Susan Cox · Barbara Francis · Michelle Mcintosh · Brian Lilley European Journal of Drug Metabolism and Pharmacokinetics, 2020, Doi : 10.1007/s13318-020-00624-6 Abstract Background : There is increasing interest in the use of purified cannabidiol (CBD) as a treatment for a wide range of conditions due to its reported anti-inflammatory, anxiolytic, antiemetic and anticonvulsant properties. Objective : The objective of this study was to assess the [...]
Lire la suiteThe Reemergence of Ketamine for Treatment in Critically Ill Adults Kimberly P. Hurth, Kristen B. Thomas, Michael A. Rudoni Critical Care Medicine, 2020,1-13. Doi : 10.1097/CCM.0000000000004335 Objectives : To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population. Data Sources : A literature review was performed using PubMed evaluating primary literature published until August 2018. Study Selection : Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis. Uses of [...]
Lire la suiteSmoking weed and coronavirus : Even occasional use raises risk of Covid-19 complications By Sandee LaMotte, CNN Updated 1222 GMT (2022 HKT) April 10, 2020 (CNN)If you're smoking weed to ease your stress during the coronavirus pandemic, experts say it's time to think twice. Smoking marijuana, even occasionally, can increase your risk for more severe complications from Covid-19, the disease caused by the novel coronavirus. Coronavirus symptoms: 10 key indicators and what to do "What happens to your airways when you smoke cannabis is that it causes some degree of inflammation, very similar to bronchitis, very similar to the type of inflammation that cigarette [...]
Lire la suiteLE CBD EST-IL PSYCHOACTIF ? François-Olivier GAGNON-HÉBERT – Chercheur Postdoctoral/ Université de Moncton, Canada La Lettre du RESPADD, 2019, 36, 4-5 https://www.respadd.org/lettre-n36-octobre-2019/ Il semble y avoir une véritable résurgence du cannabis dans les débats publics à l’échelle internationale depuis quelques années. Cette plante cultivée depuis les premiers balbutiements des sociétés humaines néolithiques grégaires (Warf 2014) ne laisse personne indifférent. Bien que les apologistes et les détracteurs de l’usage de la plante ne s’entendent généralement sur aucun point, tous s’entendent sur la réalité suivante : il s’agit d’une question fort complexe et épineuse. Au-delà des débats moraux et sociétaux, il n’en demeure pas moins que le cannabis [...]
Lire la suiteThe Psychiatric Consequences of Cannabinoids Joao P. De Aquino, Mohamed Sherif, Rajiv Radhakrishnan, John D. Cahill, Mohini Ranganathan and Deepak C. D’Souza Clinical Therapeutics, 2018, 40, (9), 14481456 Doi : 10.1016/j.clinthera.2018.03.013 ABSTRACT With rising rates of cannabis use in the general population and an increasing number of US states legalizing both recreational and medical cannabis use, it is important to be informed about the adverse consequences of cannabinoids. This Commentary provides an overview of the psychiatric effects of plant-based and synthetic cannabinoids, differentiating acute effects from effects associated with persistent use. Cannabinoids produce multiphasic and dose dependent effects on anxiety, mood, and perception, in addition [...]
Lire la suiteMedical Marijuana Use in Oncology : A Review Gianna Wilkie, Bachir Sakr, Tina Rizack JAMA Oncology, 2016, 2, (5), 670-675. doi:10.1001/jamaoncol.2016.0155 IMPORTANCE : Medicinal marijuana use is currently legal in 23 states and the District of Columbia. As more states approve marijuana use for medical indications, physicians will be asked by their patients for more information regarding the risks and benefits of use. This article reviews the history, adverse effects, and proposed mechanisms of action of marijuana and summarizes the available literature regarding symptom relief and therapeutic value in patients with cancer. OBSERVATIONS : Marijuana in oncologymay have potential for use as an antiemetic, for [...]
Lire la suite